Alberta Cancer Foundation announces initial investment of its novel philanthropic Breakthrough Fund to support early-stage cancer research
This Fund evolves the traditional model of philanthropy, positioning donors as investors in the health and wealth of the community.
- This Fund evolves the traditional model of philanthropy, positioning donors as investors in the health and wealth of the community.
- “The Alberta Cancer Foundation recognized the need to actively move ideas from research through to market in order to truly transform patient outcomes, survival rates and quality of life,” said Wendy Beauchesne, CEO, Alberta Cancer Foundation.
- Earlier this month, the Alberta Cancer Foundation was pleased to announce Entos Pharmaceuticals and 48Hour Discovery were each awarded $100,000 to advance their research in cancer treatment options.
- Recent cancer immunotherapy treatment advancements demonstrate the effectiveness of personalized DNA vaccines and Entos plans to use Breakthrough funding to propel its research to the next stage.